Global In-Vitro Fertilization Market by Technology (Conventional IVF, ICSI (Intracytoplasmic Sperm Injection)), by Application (Female Infertility, Male Infertility), by End-Use (Fertility Clinics, Hospitals, Research Institutes), and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the In-Vitro Fertilization Market was valued at USD 17.8 Billion in 2024-e and will surpass USD 31.5 Billion by 2030; growing at a CAGR of 10.0% during 2025 - 2030.

The in-vitro fertilization (IVF) market has experienced significant growth in recent years, driven by advancements in reproductive technologies, increased awareness of fertility treatments, and rising infertility rates across the globe. IVF has emerged as one of the most effective assisted reproductive technologies (ART) for couples struggling with infertility, offering hope for individuals seeking to conceive. IVF involves the fertilization of an egg outside the body, with the resulting embryos then being implanted in the uterus. As fertility treatments gain popularity, the IVF market has expanded to include various technologies and techniques, catering to a wide range of applications, including female and male infertility.

Technological innovations, improved success rates, and greater accessibility have made IVF more prevalent in recent years. The market continues to evolve, with new developments in embryo culture, egg freezing, genetic testing, and cryopreservation. The growing number of fertility clinics, advancements in IVF-related technologies, and shifting societal attitudes towards family planning are expected to continue fueling the IVF market’s growth. Additionally, the increasing prevalence of infertility due to lifestyle factors, delayed marriages, and medical conditions has further spurred demand for IVF treatments worldwide.

Conventional IVF Is Largest Technology Segment Owing to Its Long-Established Success

The conventional IVF technique remains the largest segment in the IVF market due to its long-standing success and widespread adoption among fertility clinics and healthcare providers. Conventional IVF involves the stimulation of ovaries to produce multiple eggs, which are then retrieved, fertilized outside the body, and implanted in the uterus. Despite the emergence of advanced technologies like ICSI, conventional IVF continues to be a first-line treatment for many couples experiencing infertility, particularly in cases where both partners have no significant underlying issues.

This method's widespread use is attributed to its cost-effectiveness, established success rates, and its ability to treat a broad spectrum of infertility causes. In addition, conventional IVF remains the preferred option for many healthcare providers because it is well-researched and routinely performed in fertility clinics globally. While newer technologies offer specialized solutions for certain types of infertility, conventional IVF remains dominant due to its simplicity, proven track record, and overall success rate in assisted reproduction.

ICSI (Intracytoplasmic Sperm Injection) Is Fastest Growing Due to Its Effectiveness in Male Infertility

ICSI (Intracytoplasmic sperm injection) is the fastest growing technology segment in the IVF market, primarily driven by its high success rates in treating male infertility. ICSI is a specialized form of IVF where a single sperm is directly injected into an egg, overcoming issues like poor sperm motility or low sperm count, which often prevent fertilization in conventional IVF. As male infertility rates rise globally, the demand for ICSI has surged, positioning it as the fastest growing segment in the IVF market.

ICSI is particularly beneficial for couples where male infertility is the primary factor, and it offers high fertilization success rates even in cases of severe sperm abnormalities. With increasing awareness of male infertility and the advancements in sperm retrieval and genetic screening, ICSI has become a preferred option for many couples undergoing IVF. As the success rates of ICSI continue to improve, the segment is expected to maintain rapid growth, making it a critical component of modern assisted reproduction technologies.

Fertility Clinics Are Largest End-Use Industry Due to Specialization in IVF Treatments

Fertility clinics are the largest end-use industry in the IVF market, as they are specialized in providing comprehensive fertility treatments, including IVF. Fertility clinics offer a range of services, such as ovarian stimulation, egg retrieval, embryo culture, and embryo transfer, making them a central hub for IVF procedures. These clinics cater to patients experiencing infertility and those opting for IVF as a solution, providing personalized treatment plans, genetic counseling, and fertility preservation services.

Fertility clinics also benefit from advancements in IVF technologies, enabling them to offer more specialized services, such as genetic screening, egg freezing, and embryo cryopreservation. As a result, fertility clinics continue to be the largest segment, driving demand for IVF procedures and related technologies. The specialized nature of fertility clinics and their focus on reproductive health make them a key player in the IVF market, with continued expansion expected as more couples seek fertility treatments worldwide.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure and High Adoption Rates

North America is the largest region in the IVF market, owing to its advanced healthcare infrastructure, high rates of infertility, and widespread adoption of fertility treatments. The region, particularly the United States, is home to some of the world’s leading fertility clinics, medical centers, and IVF specialists, offering state-of-the-art technologies and treatment options. The high success rates of IVF treatments and the growing awareness of assisted reproduction have contributed to North America’s dominance in the IVF market.

In addition, North America benefits from a high level of investment in healthcare research, enabling continuous advancements in IVF technologies and reproductive medicine. The increasing number of IVF cycles performed, coupled with supportive regulatory frameworks and reimbursement policies, further strengthens the region’s position as the largest market. Furthermore, the growing acceptance of fertility treatments and the demand for advanced reproductive technologies continue to drive the growth of the IVF market in North America.

Leading Companies and Competitive Landscape

The IVF market is highly competitive, with several leading companies striving to enhance their offerings and expand their market share. Key players in the market include CooperSurgical Inc., Vitrolife AB, Ferring Pharmaceuticals, Merck KGaA, and IVF America. These companies invest heavily in research and development to introduce new technologies and improve existing IVF procedures, aiming to increase success rates and reduce treatment costs.

In the competitive landscape, companies focus on strategic partnerships, mergers and acquisitions, and expanding their geographical presence to gain a larger market share. With the growing demand for fertility treatments, key players are also investing in digital health solutions, such as telemedicine platforms, to cater to patients seeking IVF consultations remotely. As the IVF market continues to evolve, companies will increasingly focus on offering personalized solutions, improving patient outcomes, and addressing the unique needs of diverse populations seeking fertility treatments.

Recent Developments:

• Ferring Pharmaceuticals launched a new IVF medication aimed at improving the success rates of embryo implantation.
• Merck KGaA introduced an advanced IVF culture media designed to improve embryo development and patient outcomes in assisted reproductive treatments.
• Vitrolife AB acquired a leading IVF diagnostic company to expand its portfolio of reproductive health products and services.
• CooperSurgical, Inc. announced a partnership with fertility clinics to provide enhanced IVF treatment options using cutting-edge embryo freezing technology.
• Progyny, Inc. unveiled a new personalized fertility treatment platform, offering tailored IVF solutions to address individual patient needs.

List of Leading Companies:

• CooperSurgical, Inc.
• Ferring Pharmaceuticals
• Vitrolife AB
• Merck KGaA
• Cook Medical
• EmbryoTech
• Genea Biomedx
• The Baker Company
• Cryolife, Inc.
• Igenomix
• Progyny, Inc.
• AbbVie Inc.
• Becton, Dickinson and Company
• R. Daniel Associates, Inc.
• TFC Fertility

Report Scope: